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Abstract
Background: Primary graft dysfunction (PGD) is considered to be the end result of an inflammatory response
targeting the new lung allograft after transplant. Previous research has indicated that MAPC cell therapy might
attenuate this injury by its paracrine effects on the pro-/anti-inflammatory balance. This study aims to investigate
the immunoregulatory capacities of MAPC cells in PGD when administered in the airways.
Methods: Lungs of domestic pigs (n = 6/group) were subjected to 90 minutes of warm ischemia. Lungs were cold
flushed, cannulated on ice and placed on EVLP for 6 hours. At the start of EVLP, 40 ml of an albumin-plasmalyte
mixture was distributed in the airways (CONTR group). In the MAPC cell group, 150 million MAPC cells (ReGenesys/
Athersys, Cleveland, OH, USA) were added to this mixture. At the end of EVLP, a physiological evaluation
(pulmonary vascular resistance, lung compliance, PaO2/FiO2), wet-to-dry weight ratio (W/D) sampling and a
multiplex analysis of bronchoalveolar lavage (BAL) (2 × 30 ml) was performed.
Results: Pulmonary vascular resistance, lung compliance, PaO2/FiO2 and W/D were not statistically different at the
end of EVLP between both groups. BAL neutrophilia was significantly reduced in the MAPC cell group. Moreover,
there was a significant decrease in TNF-α, IL-1β and IFN-γ in the BAL, but not in IFN-α; whereas IL-4, IL-10 and IL-8
were below the detection limit.
Conclusions: Although no physiologic effect of MAPC cell distribution in the airways was detected during EVLP, we
observed a reduction in pro-inflammatory cytokines and neutrophils in BAL in the MAPC cell group. This effect on
the innate immune system might play an important role in critically modifying the process of PGD after
transplantation. Further experiments will have to elucidate the immunoregulatory effect of MAPC cell administration
on graft function after transplantation.
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Background
In the year 2016, lung transplantation has grown into a
successful treatment option for patients with end-stage
pulmonary disease. However, severe primary graft dys-
function (PGD) still occurs in up to 30% of transplanted
patients. And although there is a low mortality of PGD
due to successful supportive therapy nowadays, patients
with severe PGD have poorer long-term outcome and a
higher risk for developing chronic lung allograft dysfunc-
tion (CLAD). PGD is the end result of ischemia-
reperfusion injury (IRI) attacking the integrity of the
capillary-alveolar membrane leading to pulmonary
edema and impaired oxygenation [1, 2]. It is based on an
inflammatory cascade that is triggered by hypoxic stress
and activation of donor macrophages, which attracts
many recipient neutrophils to the donor lung upon re-
perfusion in the recipient chest. Bone marrow-derived
mesenchymal cells possess immunoregulatory capabil-
ities and could therefore be of particular interest to at-
tenuate PGD. They are already found to be a successful
treatment option for patients suffering from acute re-
spiratory distress syndrome, which shares a similar in-
flammatory pathophysiology with PGD [3–5]. More
specifically, pilot studies show that they can reduce IRI
inherent to solid organ transplantation in the lung [6–8],
but also in other organ systems [9, 10]. Here, their bene-
ficial effects result from paracrine mechanisms and cell-
cell interaction rather than engraftment and repair of
diseased tissue [11]. An altered inflammatory balance,
with a decrease in pro-inflammatory and increase in
anti-inflammatory cytokines, is observed [6]. In hypoxic
conditions, such as ischemic injury models, secretion of
growth factors such as VEGF and ANG-1 can stimulate
angiogenesis and tissue repair [8, 12]. Mordant et al. re-
cently published their results on mesenchymal stem cell
(MSC) administration to a porcine donor lung on ex
vivo lung perfusion (EVLP), which resulted in a reduc-
tion of interleukin (IL)-8, however, there was no effect
on physiological parameters detected [13]. The role in
a reduction of inflammatory cytokines in an acellular
ex vivo perfusion set-up therefore still has to be
unraveled.
There are two types of bone marrow-derived cells that
are well characterized and could be good candidates for
immunoregulation of the IRI pathophysiology: the mes-
enchymal stem cell (MSC) and multipotent adult pro-
genitor cell (MAPC) [14]. Both have similar
immunoregulatory capabilities, but are characterized as
individual cell types and adopt different phenotypes
under certain culture conditions [15]. One of the most
advantageous characteristics of the MAPC cells is their
large proliferation capacity and low senescence. There-
fore, large batches of stem cells can be produced from
one healthy donor [16, 17]. A clinical-grade MAPC
product (MultiStem®, Athersys, Cleveland, OH, USA)
has been developed for phase I and II clinical testing.
The MultiStem clinical-grade product is based on
MAPC cell isolation and expansion protocols under
good manufacturing practice conditions [18, 19]. Our
previous research indicates that intratracheal administra-
tion of cells holds the greatest potential to reduce IRI
based on a reduction in lung edema formation. However,
after administration of 10 million MAPC cells in the air-
ways, a physiological improvement of lung function was
not detected nor was there an alteration in the inflam-
matory environment of the lung tissue. Therefore, in this
study we increased the dosing regimen to an intermedi-
ate dose of 3.75 million/kg in order to investigate a
physiological improvement of lung function and to study
this mechanism based on immunoregulation. Also for
other solid organ transplant research, this intermediate
dosing regimen of 3.5–4.5 million cells/kg has led to an
improved graft function after transplantation [4, 9, 10].
In order to administer these cells, ex vivo lung perfu-
sion (EVLP) has been put forward as a treatment plat-
form of ex vivo organ reconditioning. EVLP is a
preservation technique of donor lungs in normothermic
conditions, allowing for continuous evaluation of the
donor lung by perfusing and ventilating the graft in an
ex vivo lung perfusion device. EVLP allows for assess-
ment of higher-risk donor lungs and might serve as the
ideal platform for active treatment since donor and re-
cipient remain unharmed, and the treatment effect can
be immediately evaluated by interpretation of the
physiological parameters [20, 21].
The immunoregulatory properties of MAPC cells have
not been widely studied in preclinical large animal
models and most preliminary theories of working mech-
anisms are based on in vitro and rodent models. There-
fore, in this large animal study, we aim to investigate if
MAPC cell delivery in the airways during EVLP (i.e.,
post-conditioning), can modulate the inflammatory
process linked to IRI by immunoregulatory effects.
Methods
This experimental study was performed in compliance
with the European Directive 2010/63/EU on the protec-
tion of animals used for scientific purposes. The princi-
ples of laboratory animal care published by the National
Institute of Health Volume 25, No. 28 (revised 1996)
were followed. Local ethics approval was obtained at the
research institute (Animal Ethics Committee Katholieke
Universiteit Leuven Belgium, NTS P043/2014).
Donor procedure
Domestic pigs Topig 20 (mean 40.8 kg) were divided
into two groups (n = 6/group). Animals were anesthe-
tized with an intramuscular injection of 5 mg/kg Zoletil
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100 (Virbac, Carros, France) and 3 mg/kg Xyl-M 2%
(VMD, Arendonk, Belgium). Anaesthesia was main-
tained using 10 mg/kg/h propofol, 20 μg/kg/h fentanyl
and intermittent boli of pancuronium 2 mg for muscle
relaxation. Animals were intubated with a 7.0 mm endo-
tracheal tube and ventilated (Aestiva 3000; GE Health-
care Europe GmbH, Little Chalfont, UK) with a tidal
volume (TV) of 8 ml/kg, positive end-expiratory pres-
sure (PEEP) of 5 cmH2O and FiO2 of 30%. Respiratory
rate (RR) was adjusted to the end-tidal carbon dioxide
(ETCO2) (45–55 mmHg). Blood pressure was monitored
invasively in the right carotid artery. All animals died of
cardiac arrest, which was induced by direct electrical
stimulation of the myocardium with an electrical pulse
generator that led to ventricular fibrillation. Animals
were disconnected from the ventilator when cardiac ar-
rest was induced. Prior to cardiac arrest, all animals were
heparinized with 300 IU/kg.
Following cardiac arrest in the donor, grafts were left
untouched in the deceased donor for 90 minutes after
which they were flushed antegradely with 50 ml/kg cold
thromethamol-buffered OCS Solution (Transmedics,
Andover, MA, USA). The heart-lung block was excised
and a retrograde flush (1 L thromethamol-buffered OCS
solution) was performed at the back table. Lungs were
instrumented on ice for a short period of time (mean
64.4 minutes) while the XVIVO (Göteborg, Sweden)
cannulas were secured in the pulmonary artery and atrial
cuff. An 8.0-mm ET tube was secured in the trachea.
The donor procedure was performed as previously
described [22].
Multipotent adult progenitor cell preparation
Human MAPC cells were isolated by Athersys/Regenesys
(Athersys, Cleveland, OH, USA; Regenesys, Heverlee,
Belgium) from bone marrow of healthy volunteers. A
research-grade variant of the clinical product was used:
cells were cultured under the same medium conditions as
MultiStem®, but not in a Good Manufacturing Practice
(GMP) environment. Isolation and cultivation of the
MAPC cells were based on previously published protocols
[19, 23]. The Quantum Cell Expansion System (Terumo
BCT, Lakewood, CO, USA) was used for ex vivo expan-
sion of large batches of MAPC. All cell batches were
subjected to several quality control assays to test if all
MAPC cell criteria were met. First of all, cell quality is
assessed by measuring viability and plating efficiency post-
thawing. Cells were thawed at a population doubling of
29.4 and had a post-thawing viability of ≥ 96%. Second,
cells are identified using qPCR and flow cytometry to test
both negative and positive markers [15, 24]. A tube forma-
tion assay is done to define the proangiogenic activity
[25], a CFSE assay [26] is performed for evaluating the im-
munoregulatory capacity.
Ex vivo lung perfusion
Lungs are perfused ex vivo with an acellular albumin
containing dextran solution. The production of the per-
fusate and technique of EVLP are performed as de-
scribed previously [27]. After a 1-hour rewarming period
and slow increase of the flow to 40% of the estimated
cardiac output (calculated as 100 ml/kg) lungs were fur-
ther perfused and evaluated for 6 hours in total. Once
the outflow temperature reaches 34 °C, ventilation was
started with 7 ml/kg tidal volume for 7 breaths/min with
5 cmH2O PEEP. In the CONTR group, 40 ml of acellu-
lar albumin (2.5%)-plasmalyte mixture was distributed
with a bronchoscope throughout the lung when ventila-
tion was started. In the MAPC cell group, 150 million
MAPC cells were added to this mixture. The study
protocol is outlined in Fig. 1. Cells were thawed, PBS
washed and diluted in 40 ml of the albumin-plasmalyte
mixture after confirming that the donor lungs were free
of adhesions or infiltrates. During 6 hours of EVLP, dy-
namic lung compliance (Compl), oxygenation [partial
oxygen pressure over fractional inspired oxygen concen-
tration (PaO2/FiO2)] and pulmonary vascular resistance
(PVR) was recorded hourly.
Tissue sampling
At the end of the experiment, tissue samples were taken
for histological evaluation and wet-to-dry-weight (W/D)
ratio calculation (after 48 hours in the oven at 80 °C).
Pathology samples are scored by an experienced path-
ologist (EV) for congestion, neutrophil influx and necro-
sis. Bronchoalveolar lavage (BAL) with two times 30 cc
saline 0.9% was performed in the right middle lobe.
Pooled fractions were returned and a cytospin (100 μl)
Fig. 1 Study protocol with n = 6/group. BAL bronchoalveolar lavage, CONTR control group, EVPL ex vivo lung perfusion, MAPC multipotent adult
progenitor cell
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was stained with Diff-Quick (Dade Behring, Newark, NJ,
USA) to perform total and differential cell counts. The
BAL supernatant was analyzed with a porcine multiplex
ELISA kit for IL-1β, IL-4, IL-8, IL-10, interferon (IFN)-γ,
IFN-α and tumor necrosis factor alpha (TNF-α) accord-
ing to the manufacturer’s protocol (Thermo Fisher Sci-
entific Inc., Waltham, MA, USA). The left lung was
inflated at 25 cmH2O, frozen solid in the fumes of liquid
nitrogen and scanned with Siemens Somaton CT scan-
ner (Siemens Healthcare, Erlangen, Germany). Lung
mass, volume, and density were measured on the basis
of the computed tomography (CT) scan, using imaging
software (Horos®) in which the lung is manually delin-
eated and the number of voxels and mean density of the
voxels within the volume is determined [28].
Statistical analysis
All data are expressed as median with interquartile range
(IQR) when depicting physiological variables in time or
as a scatter plot with median and IQR when comparing
variables at the end of the experiment (GraphPad Prism
4, GraphPad Software Inc., La Jolla, CA, USA).
Mann-Whitney tests were conducted in GraphPad to
compare data at the end of EVLP. We analyzed end-
experimental parameters only to dichotomize between ac-
ceptable and non-acceptable lungs. Baseline parameters of
the donor animals are described as median (25% QI –
75% QI) and are analyzed with the same statistical test.
The level of statistical significance was set at p < 0.05.
Results
Baseline
Baseline animal parameters and the perfusate are similar
between both groups (Table 1).
Physiological assessment
Physiological parameters PVR, Compl, and PaO2/FiO2
are depicted over time (hours on EVLP) in panel a-c of
Fig. 2. All data points are depicted as median +/- IQR.
Physiologic parameters at the end of EVLP, are
depicted in panel d-f. No statistical differences were de-
tected in PVR (p = 0.68), Compl (p = 0.22) or PaO2/FiO2
(p = 0.13) between the two groups.
Lung edema estimation
W/D of the tissue sample of the right lower lobe and
CT density calculation of the left inflated frozen lung
did not reveal a statistical difference between both
groups (Fig. 3). Administration of 150 million stem cells
did not result in attenuation of lung edema formation in
the warm ischemic-injured porcine lungs.
Histology
No significant differences were detected in the injury
scores for both groups for the presence of congestion (p
= 0.92), necrotic cells (p = 0.70) or influx of neutrophils
(p = 0.56) (Fig. 4).
Inflammation bronchoalveolar lavage fluid
Quantitative determination of IL-1β, IL-4, IL-8, IL-10,
IFN-γ, IFN-α, and TNF-α in BAL fluid showed a signifi-
cant reduction of TNF-α, IL-1β, and IFN-γ while IFN-α
was similar in both groups (Fig. 5). IL-4, IL-8, and IL-10
were below the detection limit.
Cell pellet analysis of the returned fractions of the BAL
fluid showed a trend toward reduction in total cell count
in the MAPC cell group (p = 0.09). Also, differential cell
count showed a significant reduction in neutrophils (p =
0.02). Results are depicted as median (25% QI – 75% QI)
in Table 2.
Discussion
In this study, we report the immunoregulatory effects on
pulmonary IRI, of MAPC cell administration in the air-
ways. Distribution of 150 × 106 MAPC cells in the air-
ways of warm-ischemic porcine donor lungs resulted in
Table 1 Baseline animal parameters and perfusate composition
CONTR MAPC p value
Baseline animal
Weight (kg) 40.3 (38.8–41.2) 42.3 (40.2–43.1) 0.10
Vt (mL/kg) 7.9 (7.8–8.0) 7.9 (7.8–7.9) 0.85
HR (bpm) 88 (73–118) 107 (94–148) 0.17
MAP (mmHg) 102 (90–113) 96 (77–106) 0.42
Peak Awp (cmH2O) 19.5 (18.8–21.3) 18.5 (17.5–19.3) 0.16
PaO2/FiO2 (mmHg) 413 (399–455) 405 (376–421) 0.37
WBC (109/L) 19.8 (14.3–24.7) 18.5 (15.2–21.2) 0.62
Neutrophils (%) 42.5 (32.3–51.0) 46.0 (37.5–52.5) 0.68
Perfusate composition
Albumin (g/L) 65.5 (64.0–66.9) 66.8 (63.5–68.8) 0.47
Osmolality (mmol/kg H2O) 318 (614–320) 318 (315–319) 0.85
Na (mmol/L) 154 (154–156) 155 (153–156) 0.79
K (mmol/L) 3.5 (3.5–3.6) 3.5 (3.5–3.6) 0.51
CI (mmol/L) 105 (104–106) 105 (104–105) 0.29
Bicarbonate (mmol/L) 31.2 (29.6–31.9) 32.6 (30.6–33.1) 0.16
Ca (mmol/L) 0.57 (0.55–0.57) 0.53 (0.52–0.56) 0.10
Glucose (mg/dL) 233 (230–239) 236 (229–248) 0.98
Comparable animal weight and baseline hemodynamic parameters. No signs
of systemic inflammation (normal WBC count, normal neutrophil count,
normal temperature). Perfusate composition is similar between both groups
for albumin, osmolality, glucose, and electrolytes.
CONTR control group, MAPC multipotent adult progenitor cell, Vt tidal volume,
HR heart rate, MAP mean arterial pressure, Peak AwP peak airway pressure,
PaO2/FiO2 partial oxygen pressure/fractional inspired oxygen concentration,
WBC white blood cell count, Na sodium, K potassium, Cl chloride, Ca calcium
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a decreased concentration of TNF-α, IL-1β, and IFN-γ
in the BAL supernatant. Also, a decreased percentage of
neutrophils and a trend to a lower total cell count in the
BAL cell pellet was observed. The attenuation of this in-
flammatory response to warm-ischemic injury, was not
reflected by an improvement in physiologic parameters,
histology or lung edema during EVLP assessment.
Up to now, bone marrow-derived MSC are most
frequently used for immunoregulation of the inflam-
matory response to pulmonary ischemia-reperfusion
injury [29, 30]. MAPC cells are also bone marrow-
derived mesenchymal cells and share many similarities
with the MSC, however in different culture conditions
they adapt different phenotypes [15]. The interest in
the use of cellular treatment for ischemia-reperfusion
injury results from in vitro evidence of their immuno-
regulatory capacities published in the last decade [31].
This immunoregulation is mainly described as the
suppression of regulatory T cells in vitro [16] while
the interaction with neutrophils, the most important
effector cell in IRI, is largely unexplored. MSC and
MAPC share similar immunoregulatory capabilities,
although MAPC cells are found to be more potent
compared to MSC in rhesus monkeys [32], human
MSC and MAPC share similar immunoregulatory
capabilities [23, 26, 33]. However, MAPC cell therapy
is privileged over MSC for clinical translation since
their low senescence and high population doubling al-
lows for banking of large batches of cells from a sin-
gle donor [15]. A clinical-grade product of MAPC,
MultiStem, is produced by Athersys and is already being
tested in phase I and II clinical trials (Athersys, Cleveland,
OH, USA). Therefore, we chose this cell type as bone
marrow-derived cellular treatment for attenuation of
ischemia-reperfusion injury in lung transplantation. Also,
xenotransplantation and allotransplantation of these cells
Fig. 3 Lung edema, estimated here with W/D and CT density, is not reduced in the MAPC cell group. Data are depicted as boxplot, and compared
with a Mann-Whitney test. CONTR control group, CT computed tomography, MAPC multipotent adult progenitor cell, W/D wet-to-dry weight ratio
Fig. 2 Monitoring of PVR (a), Compl (b) and PaO2/FiO2 (c) during 6 hours of EVLP. The final assessment at the end of EVLP did not show any
statistical difference between both groups for PVR (d), Compl (e) or PaO2/FiO2 (f). BAL bronchoalveolar lavage, Compl dynamic lung compliance,
CONTR control group, EVPL ex vivo lung perfusion, MAPC multipotent adult progenitor cell, PaO2/FiO2 partial oxygen pressure/fractional inspired
oxygen concentration, PVR pulmonary vascular resistance
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is thought to be safe due to a low expression of MHC I
and lack of MHC II expression [14, 33]. These immune-
privileged properties avoid recognition by the recipient’s
immune system, and therefore, this immune mismatch is
generally believed not to be an increased risk for patients.
We used a validated injury model with exposure of the
lung graft to 90 minutes of warm ischemia [22]. This re-
sulted in an accumulation of lung edema when perfused
for 6 hours on EVLP, which is reflected by a high W/D
(median 6.6 in CONTR) and high CT density (median
245 g/L in CONTR). An inflammatory cascade with in-
filtration of neutrophils was launched upon reperfusion
of the donor lung on EVLP, even though we worked with
an acellular perfusate. This is shown by an increased
percentage of neutrophils in the BAL in the CONTR
group (median 7.7% vs. 1.7%). Most likely, these cells
were trapped in the microvasculature of the lung despite
adequate antegrade and retrograde flush of the lung
upon procurement. Also, general inflammatory markers
such as TNF-α, IFN-γ, IFN-α, and IL-1β were increased
in CONTR showing activation of the innate immune
system with interaction of macrophages, lymphocytes,
endothelial cells, and epithelial cells. A porcine multiplex
analysis was used (Thermo Fisher Scientific Inc.,
Waltham, MA, USA), however cross-reactivity between
swine and human is very typical, therefore we did not
use human-specific ELISA kits to get an insight into the
inflammatory injury microenvironment of the lung.
While Mordant et al. could show an IL-8 reduction in
the perfusate in their model of MSC therapy during
EVLP [13], the detection limit of 0.56 pg/ml for IL-8
was not reached in our BAL sample. Therefore, we can-
not speculate on the effect on IL-8 and its neutrophil
chemotaxis effect. We did report a reduction in general
inflammatory markers involved in the innate immune
system, such as TNF-α, IL-1β, IFN-γ, and saw a signifi-
cant reduction in neutrophils in the BAL sample. While
these immunoregulatory effects are highly significant,
they were not reflected by an improved graft function on
EVLP evaluation. The exact effect of this immunoregula-
tory effect, therefore, has to be further unraveled in a
Fig. 4 No differences were seen in the injury severity score for
congestion, presence of necrosis, and neutrophils. CONTR control
group, MAPC multipotent adult progenitor cell
Fig. 5 Significant reduction of inflammatory markers TNF-α, IL-1β, and IFN-γ in BAL CONTR control group, IFN interferon, IL interleukin, MAPC multipotent
adult progenitor cell, TNF-α tumor necrosis factor alpha
Table 2 Total cell count (TCC) and differential cell count of BAL
fluid cell pellet
CONTR MAPC p value
TCC (×106 cells/ml) 1.2 (0.9–1.5) 0.8 (0.7–1.0) 0.09
Macrophages (%) 88.5 (84.2–91.9) 95.3 (91.4–97.2) 0.06
Neutrophils (%) 7.7 (6.5–13.5) 1.7 (1.2–4.4) 0.02
Lymphocytes (%) 2.5 (0.8–3.9) 3.0 (1.7–3.7) 0.79
BAL bronchoalveolar lavage, CONTR control group, MAPC multipotent adult
progenitor cell
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transplant experiment where the lung graft is reperfused
with a pulsatile flow of whole blood and the full impact
of IRI can be studied.
In our model, MAPC cells were administered in the
airways. This route of administration is based on the
pathological findings of ischemia-reperfusion injury
and acute respiratory distress syndrome, which share
a similar pathophysiology. In the acute phase of IRI,
epithelial denudation leads to loss of the epithelial
cell layer over much of the basal membrane (in com-
bination with lesser endothelial damage such as cell
swelling, widening of the intercellular junctions, and
increased number of pinocytotic vesicles) [34, 35].
Since diffuse alveolar damage in the acute phase is
thus primarily based on epithelial cell injury, we
aimed at targeting the epithelial side of the alveolar
membrane with our cellular therapy.
Also, dose-response studies will have to be further
conducted to determine the maximal effect. In this
study, an intermediate dose of 3.75 million MAPC/kg
body weight was administered. In mice studies, 0.5 to
2 million cells are usually administered, which corre-
sponds to 100 to 200 million cells/kg. These doses
are probably irrelevant for clinical practice since we
also have to watch out for entrapment of these large
cells (15–19 μm) in the microvasculature of the lung
with microthrombi formation, increased PVR and
hydrostatic pulmonary edema as potential dangerous
consequence. A low dose of 0.24 million cells/kg has
been shown not to be effective to tackle IRI as re-
ported by our group previously [36]. It might there-
fore be that one should be looking for an optimal
dose instead of a linear dose-response effect. A dose-
response study would therefore be much more
insightful to distinguish between low efficacy or
underdosing of our investigated therapy in this ex-
perimental animal model.
La Francesca et al. previously investigated the effect
of MAPC instillation in the airways to improve lung
quality for transplantation [7]. However, in their
study, MAPC cells were instilled in the left lower
lobe while the right lower lobe was used as control.
Due to perfusion differences between the left and
right lung on EVLP, we often see that after prolonged
EVLP the left lung is macroscopically better preserved
than the right lung. Therefore, we wanted to investi-
gate the effect of MAPC cells instilled in the airways
with two different test groups rather to use the right
lower lobe as a control.
Finally, we acknowledge that biodistribution of our
cells could not be shown. Entrapment and localization of
the administered cells will have to be investigated to
understand the underlying mechanisms of the immuno-
regulatory capacities of cellular therapy.
Conclusions
In conclusion, we can state that, although no physiologic
effect of immunoregulation was detected during EVLP,
we did observe a reduction in pro-inflammatory cyto-
kines and neutrophils in the BAL after MAPC cell distri-
bution in the airways indicating a regulatory effect on
the innate immune system. This effect might play an im-
portant role in critically modifying the process of PGD
early after transplantation [37]. The innate immune sys-
tem is also involved in the etiology of bronchiolitis oblit-
erans syndrome (BOS) [38], and therefore MAPC cell
administration early in the process of lung transplant-
ation might have an effect on the development of BOS,
the main predictor of long-term outcome. Further ex-
periments will have to elucidate the effect of MAPC cell
administration on graft function after transplantation.
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